Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for
ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81
mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up
will be 50 months. The purpose of the study is to identify the optimal dose of aspirin for
secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD). The
primary endpoint is a composite of all-cause death, hospitalization for MI, or
hospitalization for stroke. The primary safety endpoint is hospitalization for major bleeding
with an associated blood product transfusion.
Phase:
N/A
Details
Lead Sponsor:
Duke University
Collaborators:
Chicago Area Patient Centered Outcomes Research Network Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN) Greater Plains Collaborative Clinical Data Research Network Health eHeart Patient Powered Network HealthCore-Anthem Research Network Humana-HUMnet Mid-South Clinical Data Research Network Mytrus New York City Clinical Data Research Network OneFlorida Clinical Data Research Network PaTH Clinical Data Research Network Patient-Centered Outcomes Research Institute Patient-Centered Scalable National Network for Effectiveness Research Research Action for Health Network Research Action for Health Network (REACHnet) The Patient-Centered Network of Learning Health Systems